Endostar is a anti-angiogenesis product and has been launched in China . The efficacy and
safety have been defined. However, the compliance is unsatisfactory since routine i.v of
Endostar is needed for 3 to 4 hours daily during one cycle of 14 days. The continuous
intravenous infusion by using venous pump can improve the compliance.
Phase:
Phase 2
Details
Lead Sponsor:
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Treatments:
Carboplatin Docetaxel Endostar protein Endostatins Pemetrexed